Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ptc Therapeutics
(NQ:
PTCT
)
31.70
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ptc Therapeutics
< Previous
1
2
3
4
5
6
Next >
Earnings Scheduled For October 27, 2022
October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
Via
Benzinga
Reaction Is Overdone For PTC Therapeutics Pausing Huntington Trial Enrollment, Analyst Says
October 19, 2022
Via
Benzinga
PTC Therapeutics Pauses Enrollment In Huntington's Candidate Trial In US
October 19, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 19, 2022
Gainers Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 74.8% to $0.17 during Wednesday's pre-market session. The company's market cap stands at $14.1 million.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 18, 2022
Gainers
Via
Benzinga
Marten Transport, Silvergate Capital And Some Other Big Stocks Moving Lower On Tuesday
October 18, 2022
U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
What 5 Analyst Ratings Have To Say About PTC Therapeutics
October 17, 2022
Within the last quarter, PTC Therapeutics (NASDAQ:PTCT) has observed the following analyst ratings:
Via
Benzinga
Expert Ratings for PTC Therapeutics
October 17, 2022
Analysts have provided the following ratings for PTC Therapeutics (NASDAQ:PTCT) within the last quarter:
Via
Benzinga
Analyst Ratings for PTC Therapeutics
October 17, 2022
Within the last quarter, PTC Therapeutics (NASDAQ:PTCT) has observed the following analyst ratings:
Via
Benzinga
Analyst Ratings for PTC Therapeutics
September 09, 2022
Analysts have provided the following ratings for PTC Therapeutics (NASDAQ:PTCT) within the last quarter:
Via
Benzinga
PTC Therapeutics: Q2 Earnings Insights
August 04, 2022
PTC Therapeutics (NASDAQ:PTCT) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
October 12, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2022
September 12, 2022
Upgrades
Via
Benzinga
Newman Ferrara LLP Announces Corporate Governance Investigations of PTC Therapeutics (PTCT)
September 07, 2022
From
Newman Ferrara LLP
Via
Business Wire
Raymond James Says PTC Therapeutics' CHMP Backing Is 'Under Exceptional Circumstances' What's Next
May 24, 2022
Via
Benzinga
Europe's CHMP Backs Approval Of PTC Therapeutics' Gene Therapy In Rare Neurometabolic Disorder
May 20, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
Upgrades
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
September 01, 2022
Upgrades
Via
Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
July 20, 2022
Via
Benzinga
The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study
July 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
PTC Stock Has Gained 27% This Week Alone, And It's Still Sprinting
June 23, 2022
Shares of PTC stock continued a seven-day run Thursday on promising test results for its Duchenne muscular dystrophy treatment.
Via
Investor's Business Daily
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in PTC Therapeutics, Inc. with Losses to Contact the Firm
June 16, 2022
From
The Schall Law Firm
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
May 31, 2022
On Tuesday, 36 companies achieved new lows for the year.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
June 02, 2022
During the Thursday's session, 100 stocks hit new 52-week lows.
Via
Benzinga
PTC Therapeutics's Return On Capital Employed Overview
May 12, 2022
According to data from Benzinga Pro, during Q1, PTC Therapeutics's (NASDAQ:PTCT) reported sales totaled $148.74 million. Despite a 11.54% increase in earnings, the company posted a loss of $126.73...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
June 01, 2022
On Wednesday, 73 stocks hit new 52-week lows.
Via
Benzinga
Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population
March 16, 2022
Via
Benzinga
Earnings Scheduled For May 3, 2022
May 03, 2022
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Via
Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
March 13, 2022
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.